Blueberry Therapeutics have unique nanopolymer drug delivery technology which opens up huge opportunities to rapidly develop new medicines and helps us find ways to treat infection & inflammation.
Blueberry is committed to the development of innovative therapies to treat diseases where infection and inflammation are major factors.
We use cutting-edge nano polymer drug delivery technology to exploit both small molecule and biologic approaches to developing treatments.
Blueberry's CEO John Ridden was interviewed by Times writer Michael Cape. John and Michael spoke about how Blueberry benefitted [...]
The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager [...]